Surrozen (SRZN) Current Leases (2020 - 2026)
Surrozen (SRZN) posted quarterly Current Leases of $1.9 million for Q1 2026, up 61.93% year-over-year from $1.2 million in Q1 2025, and up 49.38% quarter-over-quarter from $1.3 million in Q4 2025.
Surrozen (SRZN) Current Leases (2020 - 2026) Analysis & Trends
Surrozen's Current Leases history runs 7 years deep, the most recent figure standing at $1.9 million for Q1 2026.
- In Q1 2026, Current Leases rose 61.93% year-over-year to $1.9 million; the TTM figure through Mar 2026 stood at $1.9 million (up 61.93% YoY), while the FY2025 annual figure was $1.3 million, down 29.47% from the prior year.
- Current Leases for Q1 2026 stood at $1.9 million, up from $1.3 million in the prior quarter.
- The five-year high for Current Leases was $2.6 million in Q1 2024, with the low at $1.2 million in Q1 2025.
- The 5-year median for Current Leases is $2.1 million (2022), against an average of $1.9 million.
- The sharpest annual moves came in 2025 and 2026: Current Leases sank 53.57% in 2025, then jumped 61.93% in 2026.
- Surrozen's Current Leases stood at $2.2 million in 2022, then increased by 12.17% to $2.5 million in 2023, then decreased by 26.75% to $1.8 million in 2024, then fell by 29.47% to $1.3 million in 2025, then jumped by 49.38% to $1.9 million in 2026.
- Business Quant data shows SRZN's Current Leases at $1.9 million in Q1 2026, $1.3 million in Q4 2025, and $1.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 11.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 16.75 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 21.95 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.24 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 45.93 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Surrozen | 281.63 Mn | 281.63 Mn | - | 1.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.99 Mn |
| Mar 31, 2026 | 1.93 Mn |
| Dec 31, 2025 | 1.29 Mn |
| Sep 30, 2025 | 1.24 Mn |
| Jun 30, 2025 | 1.20 Mn |
| Mar 31, 2025 | 1.19 Mn |
| Dec 31, 2024 | 1.83 Mn |
| Sep 30, 2024 | 1.53 Mn |
| Jun 30, 2024 | 2.17 Mn |
| Mar 31, 2024 | 2.56 Mn |
| Dec 31, 2023 | 2.50 Mn |
| Sep 30, 2023 | 2.43 Mn |
| Jun 30, 2023 | 2.36 Mn |
| Mar 31, 2023 | 2.29 Mn |
| Dec 31, 2022 | 2.23 Mn |
| Sep 30, 2022 | 2.16 Mn |
| Jun 30, 2022 | 2.09 Mn |
| Mar 31, 2022 | 2.14 Mn |
| Dec 31, 2021 | 2.19 Mn |
| Sep 30, 2021 | 2.22 Mn |